Table 5.

Association between LC n-3 PUFA and aggressive prostate cancer, stratified by COX-2 genotypes

COX-2 SNP
LC n-3 PUFA*
rs no. (position)GenotypeOR (95% CI)Cases/controls, quartile of intake
OR (95% CI)PtrendPinteraction§
1234
All subjects173/120119/11995/11979/1200.61 (0.46-0.81)
rs2745557GG1.0125/7787/7067/7958/750.59 (0.42-0.83)0.0020.72
    (+201)GA or AA0.65 (0.49-0.86)48/4332/4928/4021/450.51 (0.32-0.84)0.007
rs5277CC1.0122/8484/9866/9354/900.60 (0.44-0.82)0.0010.75
    (+1225)CG or GG1.38 (1.03-1.86)51/3634/2129/2625/300.48 (0.27-0.85)0.012
rs2206593GG1.0161/108110/10388/9771/1040.53 (0.39-0.71)<0.00010.14
    (+6993)GA or AA0.53 (0.34-0.81)12/119/167/228/160.96 (0.47-1.95)0.91
rs689470GG or GA1.0167/117113/11690/11473/1180.56 (0.43-0.75)<0.00010.98
    (+8364)AA2.23 (1.03-4.87)6/25/35/56/20.16 (0.01-2.01)0.15
rs4648310AA1.0158/118111/11689/11376/1130.61 (0.47-0.81)0.00060.02
    (+8897)AG or GG1.88 (1.04-3.40)15/28/36/63/70.07 (0.01-0.41)0.003
  • * EPA + DPA + DHA.

  • For main genetic effect (ignoring PUFA intake). Adjusted for age, ethnicity, and institution.

  • Stratified by genotypes. From logistic model, with LC n-3 PUFAs as a continuous variable. ORs correspond to difference between median values of quartiles 1 and 4 (0.52 g/d) unit increase in PUFAs. Adjusted for total calorie intake, age, ethnicity, and institution.

  • § Multiplicative interaction from cross-product term in logistic regression between PUFAs (continuous) and each COX-2 SNP.